English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduCardiologist Bertram Pitt, MD, sees promise in combining two new classes of medication into a treatment regimen for patients with cardiovascular disease. Pitt will discuss the advantages of this treatment plan in his plenary lecture at an American Physiological Society Conference in Estes Park, Colo.
Tag: Aldosterone and ENaC in Health and Disease
Same Receptor, Different Effect: Research Uncovers New Sex-specific Factor in CV Disease
A common receptor may serve differentiated roles related to aging-associated cardiovascular disease in males and females. Jennifer DuPont, PhD, will present the findings of this first-of-its-kind study today at the American Physiological Society Aldosterone and ENaC Conference in Estes Park, Colo.
Blocking a Hormone’s Action in Immune Cells May Reduce Heart Disease Risk
Blocking the mineralocorticoid receptor (MR)—a protein that helps maintain normal levels of salt and water in the body—in immune cells may help reduce the risk of heart attack and stroke by improving blood vessel health. The study will be presented today at the American Physiological Society (APS) Aldosterone and ENaC in Health and Disease: The Kidney and Beyond Conference in Estes Park, Colo.
Short-term Probiotics Regimen May Help Treat Gout, Kidney Disease
New research suggests that an individualized probiotic therapy regimen may improve symptoms of gout, gout-related kidney disease and other signs of metabolic syndrome. The study will be presented today at the American Physiological Society (APS) Aldosterone and ENaC in Health and Disease: The Kidney and Beyond Conference in Estes Park, Colo.